Vir Biotechnology, Inc.
corporate_fare Company Profile
Vir Biotechnology, Inc. (NASDAQ:VIR) is a publicly traded company in the Life Sciences sector. Wiseek monitors VIR SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.
Recent high-impact activity:
- Vir Biotechnology CFO Jason O'Byrne Steps Down; CAO Brent Sabatini Named Interim
- Vir Biotechnology Appoints Timothy Coughlin as New Director and Audit Committee Chair
- Vir Biotechnology to Present Complete Phase 2 Solstice Data for Hepatitis Delta
- Vir Biotechnology Finalizes Astellas Collaboration for Prostate Cancer Drug VIR-5500, Securing $315M Upfront & Equity
- Vir Biotechnology Secures $172.5M in Public Offering, Extends Cash Runway to H2 2028, and Advances Key Pipeline Programs
Financial Snapshot
Dilution Risk
Low riskFiling-implied dilution signals for VIR, detected from its recent SEC filings · based on capital-structure filings through 2026-02-24.
New Public Offering Announced · Significant Potential Dilution
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →